Related Experiment Videos
Silent myocardial ischemia: a special aspect of coronary artery disease
1Department of Internal Medicine-Cardiology, University of Bonn, Federal Republic of Germany.
Insights
Silent myocardial ischemia, a painless heart condition, requires ongoing monitoring. While its exact prognosis is unclear, intensive medical therapy and revascularization are key treatment considerations.
Area of Science:
- Cardiology
- Internal Medicine
Background:
- Silent myocardial ischemia is a progressive condition characterized by painless ST-segment depression.
- Its underlying mechanisms are similar to stable angina pectoris.
Purpose of the Study:
- To review the characteristics, prognostic implications, and treatment strategies for silent myocardial ischemia.
Main Methods:
- Review of existing literature on silent myocardial ischemia.
- Comparison of silent ischemia with symptomatic angina pectoris.
Main Results:
- Silent ischemia shares mechanisms with stable angina but lacks pain.
- Prognostic implications are not fully defined, but arrhythmogenic potential exists.
- No clear evidence shows a different prognosis compared to symptomatic ischemia.
Conclusions:
- Continuous surveillance of silent myocardial ischemia is essential.
- Intensive combination medical therapy is recommended to reduce ischemic episodes.
- Revascularization should be considered for persistent ischemic changes, though optimal treatment remains undefined.
Abstract:
Silent myocardial ischemia is a serious progressive disease which deserves continuous surveillance. It is characterized by painless ST-segment depression based on coronary artery disease. The mechanisms responsible for producing this condition do not differ from stable angina pectoris. The prognostic implications of silent ischemia are not yet completely clarified. However it could be argued that patients die--whether or not angina pectoris is present--because they develop myocardial infarction or ischemic ventricular arrhythmias. Complex ventricular arrhythmias seem to occur not at a higher rate than in patients with angina pectoris. On the other hand there is no doubt about a present arrhythmogenic potential of a silent myocardial ischemia, but there is so far no clinical evidence that the prognostic significance is different to symptomatic myocardial ischemia. In order to reduce or eliminate ischemic episodes intensive combination medical therapy should be used. If symptoms recur or ischemic changes are persistent, consideration should be given to revascularisation. Nevertheless, the optimal way of treating silent ischemia is still to be defined.